Literature DB >> 26843517

Cytoskeletal architecture and cell motility remain unperturbed in mouse embryonic fibroblasts from Plk3 knockout mice.

Daniel R Michel1, Kyu-Shik Mun2, Chia-Chi Ho2, Peter J Stambrook3.   

Abstract

Polo-like kinase 3 (Plk3) is best known for its involvement in cell cycle checkpoint regulation following exposure to cytotoxicants or induction of DNA damage. Yet, Plk3 has also been implicated in roles beyond those of cellular responses to DNA damage. Here, we have investigated the proposition, suggested by the Plk literature, that Plk3 regulates cytoskeletal architecture and cell functions mediated by the cytoskeleton. To this end, we have assayed mouse embryonic fibroblasts (MEFs) generated from both Plk3 knockout and wild-type mice. In particular, we asked whether Plk3 is involved in actin fiber and microtubule integrity, cell migration, cell attachment, and/or cell invasion. Our results demonstrate that functional Plk3 is not critical for the regulation of cytoskeletal integrity, cell morphology, cell adhesion, or motility in MEFs.
© 2016 by the Society for Experimental Biology and Medicine.

Entities:  

Keywords:  Polo-like kinase; and attachment; cell migration; cell motility; cytoskeleton; plk3

Mesh:

Substances:

Year:  2016        PMID: 26843517      PMCID: PMC4950333          DOI: 10.1177/1535370216629010

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN: 1535-3699


  42 in total

Review 1.  Actin cytoskeleton dynamics and the cell division cycle.

Authors:  Yi-Wen Heng; Cheng-Gee Koh
Journal:  Int J Biochem Cell Biol       Date:  2010-04-20       Impact factor: 5.085

Review 2.  Polo-like kinases: conservation and divergence in their functions and regulation.

Authors:  Vincent Archambault; David M Glover
Journal:  Nat Rev Mol Cell Biol       Date:  2009-04       Impact factor: 94.444

Review 3.  Polo-like kinases: a team that plays throughout mitosis.

Authors:  D M Glover; I M Hagan; A A Tavares
Journal:  Genes Dev       Date:  1998-12-15       Impact factor: 11.361

4.  Investigation on PLK2 and PLK3 substrate recognition.

Authors:  M Salvi; E Trashi; G Cozza; C Franchin; G Arrigoni; L A Pinna
Journal:  Biochim Biophys Acta       Date:  2012-07-21

Review 5.  Polo-like kinases and oncogenesis.

Authors:  Frank Eckerdt; Juping Yuan; Klaus Strebhardt
Journal:  Oncogene       Date:  2005-01-10       Impact factor: 9.867

6.  Polo-like kinase-2 is required for centriole duplication in mammalian cells.

Authors:  Silke Warnke; Stefan Kemmler; Rebecca S Hames; Hsiao-Lun Tsai; Urs Hoffmann-Rohrer; Andrew M Fry; Ingrid Hoffmann
Journal:  Curr Biol       Date:  2004-07-13       Impact factor: 10.834

7.  Replication stress, defective S-phase checkpoint and increased death in Plk2-deficient human cancer cells.

Authors:  Elizabeth M Matthew; Timothy J Yen; David T Dicker; Jay F Dorsey; Wensheng Yang; Arunasalam Navaraj; Wafik S El-Deiry
Journal:  Cell Cycle       Date:  2007-09-25       Impact factor: 4.534

8.  Cdc25C phosphorylation on serine 191 by Plk3 promotes its nuclear translocation.

Authors:  El Mustapha Bahassi; Robert F Hennigan; David L Myer; Peter J Stambrook
Journal:  Oncogene       Date:  2004-04-08       Impact factor: 9.867

9.  Polo-like kinase 3 is Golgi localized and involved in regulating Golgi fragmentation during the cell cycle.

Authors:  Qin Ruan; Qi Wang; Suqing Xie; Yuqiang Fang; Zbigniew Darzynkiewicz; Kunliang Guan; Meena Jhanwar-Uniyal; Wei Dai
Journal:  Exp Cell Res       Date:  2004-03-10       Impact factor: 3.905

10.  Correction: Nuclear receptor LRH-1/NR5A2 is required and targetable for liver endoplasmic reticulum stress resolution.

Authors:  Jennifer L Mamrosh; Jae Man Lee; Martin Wagner; Peter J Stambrook; Richard J Whitby; Richard N Sifers; San-Pin Wu; Ming-Jer Tsai; Francesco J DeMayo; David D Moore
Journal:  Elife       Date:  2015-07-24       Impact factor: 8.140

View more
  1 in total

1.  The role of polo-like kinase 3 in the response of BRAF-mutant cells to targeted anticancer therapies.

Authors:  Mahamat Babagana; Julia V Kichina; Hannah Slabodkin; Sydney Johnson; Alexei Maslov; Lorin Brown; Kristopher Attwood; Mikhail A Nikiforov; Eugene S Kandel
Journal:  Mol Carcinog       Date:  2019-09-30       Impact factor: 4.784

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.